Clinical Trial

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA…

11 months ago

TruLab Integration to Florence Streamlines Biospecimen Data Management for Clinical Sites

ATLANTA, GA / ACCESSWIRE / February 7, 2024 / TruLab, a leading provider of sample management solutions, and Florence Healthcare,…

11 months ago

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…

11 months ago

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

11 months ago

Skye Bioscience to Present at Oppenheimer Investor Conference

San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused…

11 months ago

Groundbreaking Digital Health Platform Set to Transform Healthcare in the UK

LONDON, UK / ACCESSWIRE / February 7, 2024 / An innovative digital health platform is transforming how medical professionals manage…

11 months ago

IRLAB Publishes Year-end Report for the Period January-December 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / February 7, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for…

11 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

11 months ago

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

11 months ago